Skip to main content
Equibles
EOLS logo

EOLS · Evolus, Inc.

Track EOLS — free

Use EOLS with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about EOLS

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$8.16 +0.14 (+1.68%) At close · Aug 14
Market Cap
$538.64M
Shares
66.05M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$8.16 Open$8.02 Day$7.91–8.26 52W close$3.94–8.34 Avg vol 30d945K Short int5.6M · 8.4% float · 8.7d Short vol50% Last earningsAug 5, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 5

Up next

Next earnings call
Nov 6, 2026 Est · unconfirmed · in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 5, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Fair Quant / Vol Very High
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +38%
      above
      Price vs 50-day avg +22%
      above
      RSI (14) 72
      overbought
      MACD trend Positive
      52-week position 96%
      near high
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Strong
      1-month return +42%
      trailing
      6-month return +88%
      trailing
      YTD return +23%
      this year
      Relative strength +75%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bullish
      Trend (MA cross) No cross
      50d $7 › 200d $6 — 50d above 200d
      Institutional flow Accumulating
      +5% holders QoQ · +33 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      8.43% of float · ▼ -5.7% MoM · 8.7 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      156 holders — mid 3-yr range
      Squeeze score 88
      high risk · 0–100
      Fundamentals
      Fair
      Revenue growth +12%
      Y/Y
      Gross margin 66%
      contracting
      EPS growth +1%
      Y/Y
      Free cash flow $-45.7M
      Balance sheet $92.3M
      net debt
      Quant / Vol
      risk profile
      Very High
      Volatility 67%
      annualized · 1-yr
      Max drawdown −49%
      past year
      ATR 5.0%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 2 of last 2
      Latest guidance · from the 8-K filed Aug 5, 2026
      Full-Year 2026
      Net Revenue $330M – $337M
      Non-GAAP Operating Expense Non-GAAP $212M – $216M
      Adjusted Gross Profit Margin 67% – 67.5%
      Full-Year 2028
      Adjusted EBITDA Margins 13% – 15%
      Total Net Revenue $450M – $500M
      Prior guidance period ended · from the 8-K filed Nov 5, 2025
      Total net revenues · full-year 2025 $295M – $305M
      Evolysse™ injectable HA gels contribution to total revenue · full-year 2025 10% – 12%
      Non-GAAP operating expenses · full-year 2025 $208M – $213M
      Non-GAAP operating income · Q4 2025 $5M – $7M
      Guided vs delivered · last 2 settled
      Total net revenues full-year 2025
      guided $295M – $305M
      $297.18M In line
      Total net revenues 2024
      guided $255M – $265M
      $266.27M Beat +2.4%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      1 · 2 · 4
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +38% Bullish
      Price vs 50-day avg
      +22% Bullish
      RSI (14)
      72 Bearish
      MACD trend
      Positive Bullish
      52-week position
      96% Bullish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) No cross
      50d $7 › 200d $6 — 50d above 200d
      Institutional flow Accumulating
      +5% holders QoQ · +33 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      8.43% of float · ▼ -5.7% MoM · 8.7 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      156 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $4 Now $8 · 96% Range high $8
      vs 200-day avg +38% vs 50-day avg +22%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Adjusted gross profit margin non-GAAP 68.5% Six Months Ended June 30, 2026 —
      Total purchasing accounts increased in the second quarter 600 Q2 2026 —
      Adjusted EBITDA non-GAAP $0.6M first quarter of 2026 —
      Evolus Rewards™ members increase vs first quarter of 2025 27% first quarter of 2026 —
      Total purchasing accounts increased 500 first quarter of 2026 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Drug Manufacturers - Specialty & Generic — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      EOLS
      Evolus, Inc.
      this stock
      		$538.64M +22.6% +11.6% — 8.4%
      JHPCY
      Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
      		 $64.91B — — — 0.0%
      TAK
      Takeda Pharmaceutical Co Ltd
      		 $56.30B +13.1% — — 0.1%
      GALDY
      Galderma Group AG/ADR
      		 $49.49B +2.4% — — 0.0%
      TEVA
      Teva Pharmaceutical Industries Ltd
      		 $42.85B +17.8% +4.3% 60.3 2.9%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      156
      % held
      74.5%
      Net QoQ
      +2.5M sh
      Top holder
      Nantahala Capital Managem…
      Held Float
      View
      Held by Funds
      Fund positions
      102
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      5.6M
      Days to cover
      8.7d
      Change
      -337.5K sh
      View
      Short Volume
      Short vol %
      50%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      2.8K
      Value
      $19.9K
      As of
      Jun 26, 2026
      View
      Off-Exchange
      Off-exchange %
      32.8%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $297.2M
      Net income (FY)
      $-51.6M
      EPS diluted
      $-0.80
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 5, 2026
      This year
      13
      View
      Proposed Sales
      Value
      $164.1K
      Shares
      16.6K
      Filed
      Jun 16, 2025
      View
      Exempt Offerings
      Offering
      $40.0M
      Filed
      Jul 17, 2020
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 5, 2026
      View
      Investor Relations
      Latest news
      Evolus Reports Strong Second Quar…
      Published
      Aug 5, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      EOLS +7.4% +42.3% +88.3% +39.6% +22.6%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY +7.0% +37.9% +74.6% +35.7% +8.8%
      Key facts CIK 1570562 CUSIP 30052C107 13F (30d) 150 filings 147 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)